NORTHAMPTON, MA / ACCESSWIRE / December 20, 2022 / Quest Diagnostics:
Presbyterian Medical Services (PMS) is an FQHC that delivers integrated healthcare, education, and services to address the needs of diverse communities across the Southwest, with a specific focus on Native American populations. PMS serves more than 9,000 patients with diabetes across New Mexico. Of those patients, one-third are not adequately managing their conditions, and are therefore at risk of developing life-threatening complications.
With Q4HE’s support, PMS is implementing the New Mexico Diabetes Prevention Action Plan, a comprehensive plan to provide intervention and support services for individuals living with diabetes. The Action Plan’s certified diabetes educators provide counseling for tribal and other community members newly diagnosed with type 2 diabetes as well as for existing patients with uncontrolled diabetes. Follow-up services are provided in person, over the phone, and virtually to better monitor patients, address questions, and ensure medication compliance. This can include regular screenings for blood pressure, BMI, and general health to monitor HbA1c levels and make referrals for additional treatment if necessary. Additionally, PMS provides supplies including home-monitoring glucometers to enable patients to monitor and report their glucose levels more regularly.
Preventive services are crucial to help patients manage their health before conditions like diabetes develop, so PMS also provides counseling and educational resources for individuals with prediabetic symptoms.
“Adult diabetes tends to be highest among Native Americans and Hispanics across our service area, and early diagnosis, education, and continuing chronic care follow-up are key factors in reducing this health disparity. The number of uncontrolled diabetes patients has also increased in the past year partly due to reduced clinic visits and lifestyle changes caused by COVID. By partnering with Quest for Health Equity, PMS can expand access to diabetes education programs and home monitoring systems. This will create pathways for consistent health education and awareness, resulting in healthy habits and long-term positive impacts in underserved populations.”
Lisa Stephens Grants and Contracts Manager, Presbyterian Medical Services
Read More
View additional multimedia and more ESG storytelling from Quest Diagnostics on

Contact Info:
Spokesperson: Quest Diagnostics
SOURCE: Quest Diagnostics

View source version on

Related Quotes
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.
Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high.
IceCure Medical, a little-known medical device company surged in after-hours trading Monday. IceCure's Prosense technology proved to be a safe and effective treatment for cancerous kidney tumors.
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
A Raleigh company is preparing a regulatory submission for its treatment for lung disease after disclosing positive results of a second late-stage study.
(Bloomberg) — Madrigal Pharmaceuticals Inc. shares surged 268%, adding about $2.9 billion to its market value, after a late-stage clinical trial of its drug candidate met the main goals in patients with a type of liver disease.Most Read from BloombergMusk Narrows Voting on Twitter Policy to Blue Members After PollJustin Bieber Urges Fans Not to Buy His Own ‘Trash’ Merchandise at H&MMusk Polls Twitter to Quit as Chief, Voters Leaning Toward YesYen Surges as Kuroda’s Yield Cap Shock Sparks Normal
BioLineRx Ltd (NASDAQ: BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors. The study met its primary endpoint of AGI-134's safety and tolerability. In this first-in-human trial, 38 patients were treated with AGI-134. Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached, and the recommended dose for
Is Pfizer stock a buy after the FDA gives it a speedy review for an older adult RSV vaccine? Is PFE stock a buy right now?
Positive late-stage results for Madrigal’s NASH treatment could rekindle the interest of larger pharmaceutical companies in this liver ailment.
Madrigal scored a win in the particularly tricky NASH field on Monday after its study hit both its goals, sending MDGL stock flying.
Children's fever and pain reductio medications are in short supply, forcing major retail pharmacies to limit purchases.
Company ends 2022 with New Drug Application (NDA) filing and Phase 2 Psoriasis Study Underway
In an utterly profound failure to read the room, Louisiana Gov. John Bel Edwards (D, supposedly) said at an end-of-year press conference on Monday that the state’s transition to adopt its near-total abortion ban “has been relatively smooth.” As Jessica Valenti pointed out in her abortion news Substack, this would be ridiculous to say in any state, really—but it’s especially so in Louisiana, where there have been several documented cases of people almost dying as a result of the ban since the fal
U.S.-listed shares of Verona Pharma Plc rallied about 39% in premarket trading on Tuesday after the company said a Phase 3 clinical trial evaluating nebulized ensifentrine as a treatment for chronic obstructive pulmonary disease met the primary and secondary endpoints. The data "support our belief that ensifentrine will change the treatment paradigm for COPD," Verona CEO David Zaccardelli said in a news release. The company plans to submit a new drug application to the Food and Drug Administrati
A late-stage trial of its drug resmetirom showed a 'best-case dataset' in resolving NASH and improving liver fibrosis.
By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT Bria-IMT Breast Cancer Efficacy Data BriaCell (NASDAQ:BCTX) attended the 2022 San Antonio Breast Cancer Symposium in early December and presented several posters summarizing data from its Phase I/IIa clinical study of Bria-IMT and reviews preclinical efforts for the company’s next generation of products. In addition to
New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs.
Such chemicals include highly durable, heat-resistant compounds that repel water, grease and stains.
Lawmakers couldn’t even agree to approve a modest bill allowing cannabis businesses access to banking.
Six children have fallen victim to flu-related deaths in the 2022 season, according to Gov. Beshear, and none of them were vaccinated.


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *